Scholarlink

Background <p>As larger population-based studies assessing neoplasm risk in neurofibromatosis 1 (NF1) are limited, we aimed to evaluate overall neoplasm risk, specific cancer types, and second primary cancers.</p> Methods <p>Using Danish registries and clinical databases, we identified 2053 individuals with NF1 and 20,530 population comparisons. We calculated cumulative incidences for first and second primary neoplasms for the study population born 1971–2020 and for adult-onset cancers in the study population born 1951–2020. We used multistate models to estimate the probabilities of being neoplasm-free, having one neoplasm, having ≥two neoplasms or being dead at a certain age.</p> Results <p>The 50-year cumulative incidence of any first neoplasm was 27.2% (95% confidence interval [CI] 23.1–31.4%) for NF1 individuals and 5.0% (4.0–6.0%) for comparisons. Moreover, the cumulative incidence of second primary neoplasm was 21.1% (14.4–27.8%) for NF1 individuals and 6.4% (0.0–15.0%) for comparisons 20 years after the first neoplasm. A person born with NF1 had a 69.8% (65.6–74.2%) probability of being alive and without neoplasm history at age 50 compared to 93.5% (92.4–94.6%) for a person without NF1.</p> Conclusion <p>The highly increased risks for primary and secondary neoplasms and mortality warrant close clinical surveillance of individuals with NF1.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neoplasm risk in individuals with neurofibromatosis 1 – a Danish nationwide cohort study with long-term follow-up

  • 期刊论文

  • 发表日期：

    2025年12月19日

查看全文
  • Mia Aagaard Doherty,
  • Kathrine Grell,
  • Hanne Hove,
  • Mette M. Handrup,
  • John R. Østergaard,
  • Anja Krøyer,
  • Thomas T. Nielsen,
  • Henrik Hjalgrim,
  • John J. Mulvihill,
  • Jan Wohlfahrt,
  • Henrik Hasle,
  • Cecilie Ejerskov,
  • Line Kenborg

摘要

Background

As larger population-based studies assessing neoplasm risk in neurofibromatosis 1 (NF1) are limited, we aimed to evaluate overall neoplasm risk, specific cancer types, and second primary cancers.

Methods

Using Danish registries and clinical databases, we identified 2053 individuals with NF1 and 20,530 population comparisons. We calculated cumulative incidences for first and second primary neoplasms for the study population born 1971–2020 and for adult-onset cancers in the study population born 1951–2020. We used multistate models to estimate the probabilities of being neoplasm-free, having one neoplasm, having ≥two neoplasms or being dead at a certain age.

Results

The 50-year cumulative incidence of any first neoplasm was 27.2% (95% confidence interval [CI] 23.1–31.4%) for NF1 individuals and 5.0% (4.0–6.0%) for comparisons. Moreover, the cumulative incidence of second primary neoplasm was 21.1% (14.4–27.8%) for NF1 individuals and 6.4% (0.0–15.0%) for comparisons 20 years after the first neoplasm. A person born with NF1 had a 69.8% (65.6–74.2%) probability of being alive and without neoplasm history at age 50 compared to 93.5% (92.4–94.6%) for a person without NF1.

Conclusion

The highly increased risks for primary and secondary neoplasms and mortality warrant close clinical surveillance of individuals with NF1.